Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Immunol. 2013 Jul 22;191(5):2258–2265. doi: 10.4049/jimmunol.1300585

Figure 6. Treatment with anti-IL-10R mAb reduces viral reactivation from latency.

Figure 6

Latently infected mice were treated with PBS or anti-IL-10R mAb for 3 weeks. Immediately after or 3 weeks after termination of treatment, TG cells from groups of 2 mice were pooled and cultured (0.15 TG/well). Cultures were treated with control IgG (A) or anti-CD8α mAb(B). Culture supernatants were serially sampled every 2 days, and assayed for infectious virus on monolayers of Vero cells and reactivation frequency was calculated (For PBS treated: 5 experiments, anti-IL-10R Treated: 2 experiments, anti-IL-10R Treated and rested: 3 experiments). Comparison of the mean reactivation frequencies between groups was performed using a square root transformation of the data presented. Statistical significance between mean reactivation frequencies was determined using an ANOVA (^ p ≤ 0.05, ^^ p ≤ 0.005). Additionally, a Fisher’s Exact Test was used to compare the number of pools that had zero reactivation events between the treatment groups (* p ≤ 0.05, ** p ≤ 0.005, *** p ≤ 0.0005).